-
JTO: Phase 3 randomized trial of SCLC preventive brain irradiation with or without hippocampal protection
Time of Update: 2021-05-08
This study is a multicenter randomized phase 3 trial, which aims to compare the neurocognitive function of patients with small cell lung cancer after PCI with or without hippocampus avoidance (HA).
-
Zynlonta, the first new ADC drug targeting CD19, has been approved!
Time of Update: 2021-05-08
On April 23, 2021, the FDA approved the antibody-conjugate drug Loncastuximab tesirine (Zynlonta) for the treatment of diffuse large B-cell lymphoma, which is still in the treatment of non-Hodgkin’s lymphoma, mantle cell lymphoma and follicular lymphoma Phase I clinical trial stage.
-
J Clin Oncol: Shocked!
Time of Update: 2021-05-08
cn/ipsen/sporty/show-details/3074/2">Digestion Approximately 300,000 people die of esophageal cancer each year in the worldAccording to the principle of radiotherapy and chemotherapy followed by surgery for esophageal cancer, preoperative radiotherapy and chemotherapy have become the standard treatment for patients with locally advanced resectable esophageal cancer or borderline cancer.
-
J Clin Oncol: Bentuximab vedodin can significantly reduce the radiation dose of children with high-risk Hodgkin's lymphoma without affecting the efficacy
Time of Update: 2021-05-08
gov/33826362/" target="_blank" rel="noopener">Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation .
gov/33826362/" target="_blank" rel="noopener">Excellent Outcome for Pediatric Patients With High- Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation in this message
-
Maintenance immunotherapy fails to prolong the survival of patients with advanced SCLC
Time of Update: 2021-05-08
This article comes from the NEJM Journal Watch Maintenance Immunotherapy for Extensive-Stage Small-Cell Lung Cancer Maintenance Immunotherapy Comment Author: Charu Aggarwal, MD, MPH For patients with no disease progression after first-line chemotherapy In patients, maintenance therapy with double checkpoint blockade failed to prolong overall survival.
-
Eur Radiol: How to identify the depth of muscular invasion of bladder cancer?
Time of Update: 2021-05-08
Recently, a study published in the journal European Radiology evaluated the diagnostic performance of the Bladder Imaging Report and Data System (VIRADS) and determined a quantitative index that complements VIRADS to predict bladder cancer myometrial invasion.
-
Zhou Guoying Comments | Oncolytic virus treatment of malignant brain tumor phase I clinical results are positive, more than 20 years of persistence finally sees the light
Time of Update: 2021-05-08
On April 12, at the 2021 American Association for Cancer Research (AACR) annual meeting, oncolytic virus therapy development company Treovir announced the clinical phase I of G207 in 12 patients with recurrent glioma (7-18 years old) Positive results of the study (NCT02457845).
-
2021 CSCO Guidelines Conference | Professor Chen Jing: Interpretation of the updated key points of soft tissue sarcoma drug treatment
Time of Update: 2021-05-08
The increased perioperative chemotherapy recommended program "CSCO Soft Tissue Sarcoma Diagnosis and Treatment Guidelines (2019 Edition)" (hereinafter referred to as "Guidelines 2019") includes the "pathological subtypes, TNM staging and IRS groupings as risk grading factors" Rhabdomyosarcoma Risk Scale.
-
"Cell Metabolism": Creatine actually promotes cancer metastasis!
Time of Update: 2021-05-08
Therefore, the article points out that creatine synthesis, or Smad2/3 pathway, may become a new target for inhibiting cancer metastasis [1].
In a mouse model injected with GATM overexpressing cancer cells, colorectal liver metastasis was significantly increased.
-
Radiology: Application of Artificial Intelligence in Breast MRI
Time of Update: 2021-05-08
Recently, a study published in the Journal of Radiology evaluated whether the diagnostic performance of radiologists in distinguishing benign and malignant lesions on breast DCE MRI images was improved compared with traditional software when using the AI system, which is the further application of AI in the clinic.
-
How safe is the new PD-L1 Nanobody "Xiaowo"?
Time of Update: 2021-05-08
*Only for medical professionals to read and refer to this comic trip, let's take a look at what Xiaowo (Envolimab) has and how safe it is! Wonderful review of past issues ☑ Phase 1: Anti-cancer guard
-
What is the tumor microenvironment?
Time of Update: 2021-05-08
In fact, the targeted therapy of macrophages can not only block the help of TAM on cancer cells, but also increase the antigen presentation to killer T cells, thereby enhancing the anti-tumor efficacy.
-
Am J Hematol: cfDNA technology to detect MYD88 L265P and CXCR4 S338X mutations in Waldenstrom's macroglobulinemia
Time of Update: 2021-05-08
gov/33819355/" target="_blank" rel="noopener">Cell-free DNA analysis for detection of MYD88 L265P and CXCR4 S338X mutations in Waldenström macroglobulinemia .
gov/33819355/" target="_blank" rel="noopener">the Cell-Free Analysis for Detection of the DNA and of CXCR4 S338X MYD88 L265P mutations in Waldenström macroglobulinemia in this message
-
Eur J Cancer: Regorafenib is expected to delay the progression of advanced chondrosarcoma that has failed chemotherapy
Time of Update: 2021-05-08
039" target="_blank" rel="noopener">Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study .
-
Adjuvant chemotherapy is beneficial to patients with stage Ⅲ MSI colon cancer
Time of Update: 2021-05-08
Microsatellite instability (MSI) stage II colon cancer patients can achieve a high postoperative survival rate without adjuvant therapy.
Compared with surgery alone, FP adjuvant therapy alone has no survival benefit for patients with stage III colon cancer with high MSI (5-year overall survival rate, 0.
-
Clin Cancer Res: Regorafenib combined with orvizumab in the treatment of microsatellite stable advanced colorectal cancer
Time of Update: 2021-05-08
org/content/27/8/2139" target="_blank" rel="noopener">Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.
org/content/27/8/2139" target="_blank" rel="noopener">Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.
-
Blood: Bentuximab combined with nivolumab in the treatment of relapsed or refractory Hodgkin's lymphoma: results of a 3-year study
Time of Update: 2021-05-08
gov/33827139/" target="_blank" rel="noopener">Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results .
gov/33827139/" target="_blank" rel="noopener">Brentuximab vedotin in Combination with nivolumab relapsed or refractory Hodgkin lymphoma in: 3-year Study Results in this message
-
NEJM: In the treatment of the most difficult breast cancer, innovative drugs bring 7 times the remission rate and double the survival time!
Time of Update: 2021-05-08
In the phase 3 trial, in patients with refractory metastatic triple-negative breast cancer, compared with chemotherapy, the drug called sacituzumab govitecan brought about 3 times the progression-free survival and 2 times the overall survival.
-
2021 CSCO Guidelines Update | Leukemia Update Key Points
Time of Update: 2021-05-08
Relapsed and refractory patients have indications for treatment, no del(17p)/TP53 gene mutations, and no matter whether there is a serious concomitant disease (CIRS score> 6 points), the level I recommendation is to add "Ibrutinib, Zebutinib, Obu" Tinib, Venecla + Rituximab/Otuzumab".
-
Behind the craze, immune cell therapy is challenging from R&D to production and quality control.
Time of Update: 2021-05-08
For example, in non-clinical research, the pharmacological characterization of immune cell therapy is special; in terms of production process, the preparation process is immature, the cost is high, and the yield is small; in terms of quality control, the starting material varies greatly, and the evaluation of efficacy and safety is complicated Difficulties that need to be overcome.
